In 2023, Berkley Life Sciences published a blog post titled PFAS “Forever Chemicals” in Medical and Life Sciences Products – Who Should Be Worried?. At that time, most per- and polyfluoroalkyl substances (PFAS) litigation to date focused on lawsuits against PFAS manufacturers, alleging personal injury from PFAS exposure. Since then, PFAS litigation has evolved, and both the U.S. Food and Drug Administration (FDA) and European Chemicals Agency (ECHA) have issued updates, warranting a fresh look at this topic.
LINKS
Read "PFAS in Medical & Life Sciences Products: A Regulatory & Litigation Update," co-authored by Lori G. Cohen, Sydney Fairchild Williamson, and Rachel Kagan on the Berkely Life Sciences website.